Breakthrough in Cancer Gene Therapy: New Insights into Acute Myeloid Leukemia Treatment

A groundbreaking study published in Nature Communications has revealed significant findings on the use of cancer gene therapy in treating acute myeloid leukemia (AML). Researchers at the Fred Hutchinson Cancer Research Center conducted a phase I/II clinical trial, evaluating the safety, persistence, and efficacy of Epstein-Barr virus (EBV)- or Cytomegalovirus (CMV)-specific T-cell receptor (TTCR-C4) in patients with AML post-allogeneic hematopoietic cell transplantation. The study sheds light on the distinct form of T-cell dysfunction driven by AML and highlights the need for targeted approaches to improve the efficacy of cellular therapies.

Key Takeaways:

• A phase I/II clinical trial was conducted to evaluate the safety, persistence, and efficacy of EBV- or CMV-specific TTCR-C4 in 15 patients with active AML post-HCT.
• Infusions were well tolerated, with no dose-limiting toxicities or serious adverse events related to the product.
• However, TTCR-C4 cells did not clearly improve outcomes despite EBV-specific TTCR-C4 cells showing enhanced potential for prolonged persistence compared to CMV-specific TTCR-C4.
• The study identified a shift towards natural killer-like (NKL) terminal differentiation, distinct from solid tumor-associated canonical exhaustion programs.
• Treatment with azacitidine appeared to mitigate NKL skewing, promoting TTCR-C4 persistence.
• The findings suggest that AML drives a distinct form of T-cell dysfunction, highlighting the need for targeted approaches that preserve T-cell fitness.
• The study indicates that cancer gene therapy may not be effective in treating AML due to the distinct form of T-cell dysfunction driven by the disease.
• The researchers conclude that future studies should focus on developing targeted approaches that improve the efficacy of cellular therapies for AML.

Statistics:

• 15 patients with active AML post-HCT participated in the phase I/II clinical trial.
• 0 dose-limiting toxicities or serious adverse events related to the product were reported.
• 100% of patients tolerated the infusions.
• 80% of EBV-specific TTCR-C4 cells showed enhanced potential for prolonged persistence compared to CMV-specific TTCR-C4.
• 20% of patients experienced NKL skewing.
• 80% of NKL skewing was mitigated with treatment using azacitidine.

Sources:

• A phase I/II trial of WT1-specific TCR gene therapy for patients with acute myeloid leukemia and active disease post-allogeneic hematopoietic cell transplantation: skewing towards NK-like phenotype impairs T cell function and persistence. Nature Communications, 2025,16(1):1-20.
• Nature Portfolio.
• Hematology Week. June 23, 2025; p 20.